Compass Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 32

Employees

  • Stock Symbol
  • CMPX

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.47
  • (As of Friday Closing)

Compass Therapeutics General Information

Description

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

Contact Information

Formerly Known As
Kairos Biologics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 80 Guest Street
  • Suite 601
  • Boston, MA 02135
  • United States

Compass Therapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Compass Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.47 $1.50 $1.15 - $3.45 $202M 138M 342K -$0.35

Compass Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 121,699 37,219 517,360 301,983
Revenue 0 0 0 0
EBITDA (43,572) (48,473) (39,681) (80,216)
Net Income (45,444) (42,494) (39,225) (82,181)
Total Assets 161,142 156,875 199,645 153,757
Total Debt 1,413 1,733 2,935 4,037
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Compass Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Compass Therapeutics‘s full profile, request access.

Request a free trial

Compass Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics i
Drug Discovery
Boston, MA
32 As of 2023
00000
000000000 00000

000000

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
0000000000000
San Diego, CA
000 As of 0000
00000
000000 - 000 00000

000000

ore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, su
0000000000000
Vancouver, Canada
000 As of 0000
00000
00000 0000-00-00
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Compass Therapeutics Competitors (98)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnaptysBio Formerly VC-backed San Diego, CA 000 00000 000000 - 000 00000
Zymeworks Formerly VC-backed Vancouver, Canada 000 00000 000000000000
Arcus Biosciences Formerly VC-backed Hayward, CA 000 00.000 000000000 00.000
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
Corvus Pharmaceuticals Formerly VC-backed Burlingame, CA 00 00000 00000000 00000
You’re viewing 5 of 98 competitors. Get the full list »

Compass Therapeutics Patents

Compass Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020208397-A1 Formulations of antibodies that bind human cd137 and uses thereof Pending 16-Jan-2019 000000000000
US-20220111047-A1 Formulations of antibodies that bind human cd137 and uses thereof Pending 16-Jan-2019 000000000000
CA-3127072-A1 Formulations of antibodies that bind human cd137 and uses thereof Pending 16-Jan-2019 000000000000
EP-3911679-A1 Formulations of antibodies that bind human cd137 and uses thereof Pending 16-Jan-2019 000000000000
US-20220090125-A1 Transgenic mouse expressing common human light chain Pending 21-Dec-2018 C12N15/8509
To view Compass Therapeutics’s complete patent history, request access »

Compass Therapeutics Executive Team (14)

Name Title Board Seat Contact Info
Vered Bisker-Leib Ph.D Chief Executive Officer & Chief Financial Officer, Finance
Thomas Schuetz Ph.D Board Member & President
Neil Lerner Vice President, Finance
You’re viewing 3 of 14 executive team members. Get the full list »

Compass Therapeutics Board Members (19)

Name Representing Role Since
Bruce Steel Self Board Observer 000 0000
Carl Gordon Ph.D OrbiMed Member of Board of Directors 000 0000
Ellen Chiniara Self Board Member 000 0000
Mary Gray Ph.D Self Board Member 000 0000
Philip Ferneau JD Borealis Ventures Board Member 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Compass Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Compass Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Compass Therapeutics‘s full profile, request access.

Request a free trial

Compass Therapeutics Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
TRIGR Therapeutics 25-Jun-2021 0000000000 000.00 Drug Discovery 000000 00
Olivia Ventures 23-Jun-2020 Merger/Acquisition Special Purpose Acquisition Company (SPAC) 000000 00
To view Compass Therapeutics’s complete acquisitions history, request access »

Compass Therapeutics Subsidiaries (1)

Company Name Industry Location Founded
TRIGR Therapeutics Drug Discovery Irvine, CA 0000
To view Compass Therapeutics’s complete subsidiaries history, request access »

Compass Therapeutics ESG

Risk Overview

Risk Rating

Updated February, 22, 2024

33.89 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,421

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 928

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 456

Rank

00.0

Percentile

To view Compass Therapeutics’s complete esg history, request access »

Compass Therapeutics FAQs

  • When was Compass Therapeutics founded?

    Compass Therapeutics was founded in 2014.

  • Who is the founder of Compass Therapeutics?

    Thomas Schuetz Ph.D, Helen Sabzevari Ph.D, Steven Tregay Ph.D, and Errik Anderson are the founders of Compass Therapeutics.

  • Who is the CEO of Compass Therapeutics?

    Vered Bisker-Leib Ph.D is the CEO of Compass Therapeutics.

  • Where is Compass Therapeutics headquartered?

    Compass Therapeutics is headquartered in Boston, MA.

  • What is the size of Compass Therapeutics?

    Compass Therapeutics has 32 total employees.

  • What industry is Compass Therapeutics in?

    Compass Therapeutics’s primary industry is Drug Discovery.

  • Is Compass Therapeutics a private or public company?

    Compass Therapeutics is a Public company.

  • What is Compass Therapeutics’s stock symbol?

    The ticker symbol for Compass Therapeutics is CMPX.

  • What is the current stock price of Compass Therapeutics?

    As of 24-May-2024 the stock price of Compass Therapeutics is $1.47.

  • What is the current market cap of Compass Therapeutics?

    The current market capitalization of Compass Therapeutics is $202M.

  • Who are Compass Therapeutics’s competitors?

    AnaptysBio, Zymeworks, Arcus Biosciences, CytomX Therapeutics, and Corvus Pharmaceuticals are some of the 98 competitors of Compass Therapeutics.

  • What is Compass Therapeutics’s annual earnings per share (EPS)?

    Compass Therapeutics’s EPS for 12 months was -$0.35.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »